AMEA
Fast, tissue-free MRD detection
for colorectal, breast, and lung cancers.1-5
Analyze thousands of epigenetic signals to achieve high sensitivity without tissue dependency.1,2
Results in <10 days.1*
Detect minimal
residual disease1
Monitor ctDNA to help
predict recurrence1
Important note: Guardant Reveal was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA.
ctDNA, circulating tumor DNA; MRD, minimal residual disease.
*Average turnaround time from sample receipt to results.